BASF Asks FDA To Weigh Whole Sunscreen TEAs, Not Separate Parts
This article was originally published in The Tan Sheet
Executive Summary
The firm’s representatives maintain a “weight-of-evidence” approach comprising repeated dose toxicity, photo-genotoxicity, dermal carcinogenicity and photo-carcinogenicity studies is adequate to establish safety. In public meetings required by the Sunscreen Innovation Act, FDA officials say BASF needs to provide more study data.
You may also be interested in...
Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations
PASS Coalition fails to find common ground with US FDA as the sunscreen access advocacy group urges significant changes to a draft guidance on safety testing for sunscreen ingredients.
Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations
PASS Coalition fails to find common ground with US FDA as the sunscreen access advocacy group urges significant changes to a draft guidance on safety testing for sunscreen ingredients.
Sunscreen Guidances Underscore FDA Standards Aren’t Changing
CDER has published guidances, required by the 2014 Sunscreen Innovation Act, on FDA’s process for advisory committees to consider firms’ sunscreen ingredient proposals and on withdrawing pending proposals being considered by the agency.